Atypical hemolytic uremic syndrome (aHUS), is mainly present in children, who have high
risks of end-stage kidney disease (ESKD), post-transplant recurrence and death. aHUS is …

Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease
largely of complement dysregulation. This advance facilitated the development of novel …

Atypical hemolytic uremic syndrome (aHUS) is an ultrarare disease caused, in most cases,
by dysregulation of the alternative complement (C′) pathway at the surface of the vascular …

Atypical hemolytic uremic syndrome (aHUS) in childhood is a rare disease associated with
high morbidity and mortality. Most cases progress to end-stage renal failure. In …

Background Atypical hemolytic uremic syndrome (aHUS) evolves into end-stage renal
failure in nearly half of affected patients and is associated with defective regulation of the …

Atypical hemolytic uremic syndrome (aHUS) is a heterogeneous disease that is caused by
defective complement regulation in over 50% of cases. Mutations have been identified in …

Atypical hemolytic uremic syndrome (aHUS) is a life-threatening multisystemic condition
often leading to end-stage renal failure. It results from an increased activation of the …

Background Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy
(TMA) characterized by platelet consumption, hemolysis, and organ damage. Eculizumab …

Background Disorders of complement regulation are the most important etiology of atypical
hemolytic uremic syndrome (aHUS). Recent studies demonstrate that eculizumab is …

The optimal duration of eculizumab treatment in patients with atypical hemolytic uremic
syndrome (aHUS) remains poorly defined. We conducted a prospective national multicenter …